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The role of DCs in primary HIV-1 infection remains uncertain. In this study, we enrolled two different groups of
subjects with acute HIV-1 infection. One group progressed to CD4 counts below 200 cells/μl within 2 years of HIV-1
infection (CD4 Low Group), while the other group maintained CD4 counts above 500 cells/μl (CD4 High Group).
We did not find statistical difference in the pDC number between the two groups during acute HIV-1 infection.
However, the mDC number was significantly lower in the CD4 Low Group than in the CD4 High Group.
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Understanding how the innate immune response affects
the outcome of HIV-1 infection in acute HIV-1 infection
will open opportunities for vaccine development that
can utilize the innate immunity to enhance viral control
with minimal pathogenesis. Dendritic cells (DCs) are
particularly important innate immune cells and HIV-1
exploits DCs to enhance infection. Thus, DCs are a
critical link between virus, CD4+ T-cells, and CD8+
T-cells. DCs are divided into two broad subsets, myeloid
(mDC) and plasmacytoid (pDC), based on phenotype,
function, and tissue localization. Although details of
these subsets are debated and vary based on species,
pDCs are specialized early type 1 interferon-secreting
cells that initiate antiviral adaptive immune responses.
mDCs differentiate from immature bone marrow (BM)-
derived precursors and function as peripheral sentinels by
transmitting antigen derived signals to draining lymph
nodes (LN). mDCs secrete high levels of interleukin-12
(IL-12) and are key players in amplifying adaptive immune
responses [1]. Early immune events during HIV infection
are associated with the rate of subsequent disease pro-
gression. A role for DCs in controlling HIV-1 replication
during primary infection has been difficult to assess, given
the difficulties in finding individuals with acute HIV infec-
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35 patients recently infected with HIV-1 were recruited
from an HIV-1-negative high-risk MSM (men who have
sex with men) cohort. They were screened every 2 m for
HIV-1 infection from October 2006 in the Beijing You’an
Hospital [2]. Thirteen of the 35 patients showed rapid pro-
gression of HIV-1 disease, with CD4 counts < 200 cells/ul
within 2 y post-infection (CD4 Low Group), while 22/35
cases enrolled in the study maintained a CD4 count higher
than 500 cells/ul (CD4 High Group). The progression of
early HIV-1 infection can be depicted as six discrete
stages, as proposed by Fiebig et al. [3]. All the 35 enrolled
patients were in Fiebig stage III. The project was reviewed
and approved by the Beijing You’an Hospital Research
Ethics Committee, and patients participated in the study
following informed consent. Demographic and immu-
nologic characteristics of the patients are reported in
Table 1.
Flow cytometric analysis
To identify DCs, the following antibodies from BD
Pharmingen (San Diego, CA, USA) were used: Lin-FITC,
CD123-PE and CD11c-APC. At least 200,000 events were
acquired for each sample. mDCs were identified as Lin-
CD123-CD11c+, while pDCs were Lin-CD123 + CD11c-
(Figure 1a). DC counts were calculated as follows, using. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Characteristics of patients in this study
Patient Age Initial CD4 count Last CD4 count Initial VL VL set point Days from the initial positive
point to CD4 < 200 cells/ul(year) (cells/ul) (cells/ul) (copies/ml) (copies/ml)
1 22 614 181 1,558 30,800 714
2 23 296 159 8,690 24,600 459
3 23 314 188 53,000 28,400 196
4 25 327 171 110,000 79,600 169
5 26 415 117 392,000 153,600 153
6 26 64 117 26,900,000 714,000 172
7 27 349 153 61,400 61,400 218
8 29 265 118 412,000 393,000 189
9 30 610 72 9,490 7,090 755
10 32 296 145 400,000 26,000 260
11 34 499 69 252,000 776,000 191
12 36 285 53 13,300 13,300 345
13 43 130 195 16,200 11,940 356
14 22 792 605 70,200 662 ━
15 23 598 714 34,000 9,700 ━
16 23 716 527 14,100 7,210 ━
17 24 805 827 56,800 35,900 ━
18 24 603 689 16,400 527 ━
19 25 552 865 9,170 1,040 ━
20 25 716 530 14,900 1,940 ━
21 26 678 622 1,440 3,260 ━
22 26 823 521 15,000 2,000 ━
23 26 805 683 258,000 61,200 ━
24 27 640 619 15,500 4,530 ━
25 29 716 546 8,780 8,390 ━
26 30 813 790 9,700 2,300 ━
27 30 745 589 8,260 1,500 ━
28 31 823 648 809 200 ━
29 32 678 546 18,500 5,200 ━
30 32 1148 1056 1,030 554 ━
31 34 558 538 26,500 9,700 ━
32 34 835 546 10,050 1,890 ━
33 37 562 568 27,600 7,960 ━
34 38 792 784 70,200 1,312 ━
35 40 720 639 6,200 3,320 ━
VL: viral load.
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flow cytometry data for DC windows, as described pre-
viously [4,5].
Absolute blood CD4+ T-cell counts were measured
using a FACSCalibur flow cytometer (BD, Franklin Lakes,
NJ, USA). Viral load was measured by the Amplicor
(Roche Diagnostic Systems, Indianapolis, IN, USA) HIV-1monitor ultrasensitive method with a detection limit of 40
copies/mL of plasma.
Assays for plasma HIV-1 RNA
Plasma HIV RNA was quantified by real-time PCR
(Roche, Germany), a super-sensitive method. The sensi-
tivity of detection of this assay was 40 copies/ml.
Table 2 Results of spearman correlation analysis
Viral load Viral load set point
pDC −0.323* −0.350*
mDC −0.233 −0.282














































Figure 1 Comparison of DCs between the three groups. (a) Analysis of pDC and mDC by flow cytometry, Comparison pDC (b) and mDC
(c) number between normal control and CD4 High Group and CD4 Low Group. Bars indicate median with interquartile range. ***p < 0.001,
**p < 0.01, *p < 0.05.
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Comparisons were performed using the nonparametric
independent sample tests, and all reported p values were
two-sided and considered significant at p < 0.05. All data
were analyzed using SPSS statistical software (version
16.0; SPSS, Chicago, IL, USA).
Results
To study the relationship between DCs and disease pro-
gression, we compared the pDC and mDC number in
Fiebig stage III between the CD4 High, CD4 Low, and
normal control groups. We found a higher pDC number
in normal controls compared with the CD4 High and
CD4 Low groups (Figure 1b). The pDC number between
the CD4 High and the CD4 Low groups did not differ
significantly (Figure 1b). However, mDCs were signifi-
cantly lower in the CD4 Low relative to CD4 High and
normal controls (Figure 1c). There was no statistically
significant difference in the mDC number between the
CD4 High and normal controls (Figure 1c). DC numbers
were negatively correlated with HIV viral load (Table 2).
Discussion
Our results are consistent with reports that DCs are
markedly reduced in number during acute HIV-1 infec-
tion [6-9], particularly pDCs. The mechanism behind
the decline in pDC numbers in acute HIV infection isnot clear. It could be because of apoptosis as a direct
result of infection [10,11] or mediated by TRAIL and
Fas ligand–Fas interactions; it could be a consequence of
compromised production of pDC precursors because of
bone marrow infection; or it may reflect pDC migration
to lymphoid tissues after HIV-induced activation.
mDCs express apolipoprotein B mRNA editing enzyme
catalytic polypeptides (APOBECs), proteins that deami-
nate cytidine to uridine in nascent minus-strand viral
DNA, blocking HIV replication [11,12]. Mature mDCs
increase APOBECG expression, explaining their relative
resistance to HIV-1 infection. mDCs capture and pro-
cess HIV-1, and present associated antigens to T-cells.
Thus, the loss of mDCs may on the one hand decrease
APOBECG expression. On the other hand, the loss of
mDCs decrease their ability of capture and process HIV-1
and present associated antigen to T cells. Therefore, this
may explain why the loss of mDC in acute HIV infection
could lead to rapid disease progression.
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than pDC from the blood during acute HIV infection is
associated with rapid disease progression. However, key
questions remain to be answered regarding tissue distri-
bution, development, and functional regulation.
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